| Document Date: 2014-06-17 10:24:01
Open Document File Size: 223,33 KBShare Result on Facebook
City Oxford / Newcastle / / Company e-Therapeutics plc / CommStrat Group / / Country United States / United Kingdom / / / Event FDA Phase / Company Listing Change / / Facility Moores Cancer Center / University of California San Diego / / IndustryTerm chemical biology / biotechnology / cancer treatment / / MedicalCondition solid tumours / secondary brain cancers / cancer / advanced solid tumours / brain cancer / disorders / / Organization Moores Cancer Center / University of California San Diego / / Person Stephen Self / Malcolm Young / Duncan Monteith / Melanie Toyne Sewell / Ted Agne / Fred Walsh / Rebecca Caygill / Daniel Elger / Stefanie Bacher / / / Position Development Director / / Product ETS2101 / formulation / / Technology pharmacokinetics / drug discovery / biotechnology / / URL www.panmure.com / www.etherapeutics.co.uk / /
SocialTag |
e-Therapeutics Begins Phase I Study of Oral Formulation of Anti-Cancer Compound ETS2101 with Healthy Volunteers 10 February 2014 – e-Therapeutics plc (AIM:ETX) announced today that it has dosed the first healthy volunt